Filing Flows › 8-K events › Parabolic Technologies
Parabolic Technologies: notice of delisting or failure to meet a listing standard
Form 8-K filed Oct 30, 2026 · items 3.01, 5.03, 5.07
What the filing says
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On October 27, 2026, Parabolic Technologies, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company
Read the filing on SEC EDGAR →
What usually followsAcross 492 8-Ks reporting Item 3.01 (delisting notice or listing-rule failure) in our universe, the stock's median move the next session was 0.0% (typical size ±2.1%, up 46% of the time); over the following 21 sessions, −0.2%. Item 5.03: +0.1% next session across 5,869. Item 5.07: 0.0% next session across 16,815. Every item ranked →
What this kind of filing means
Item 3.01 — Notice of delisting or failure to meet a listing standard. A delisting notice starts a compliance window; companies often answer with a reverse split, a plan, or a move to another market.
Parabolic Technologies at a glance
Parabolic Technologies, Q2 2026: revenue $2.3M (-27% year over year), operating margin -193.0%. The chart follows the revenue to costs, profit and cash.
Parabolic Technologies: every quarter, Q/Q and Y/Y, holders and guidance →
Parabolic Technologies’s other material 8-Ks
- Nov 5, 2026 — Share offerings Parabolic Technologies, Inc. Announces Closing of $13.5 Million Underwritten Public Offering
- Oct 21, 2026 — Share offerings
Other recent delisting notices
- Barfresh Food Group Nov 6, 2026
- Fifth Era Acquisition Corp I Nov 6, 2026
- Tempest Therapeutics Nov 6, 2026
- Roku Nov 6, 2026
- Bowman Consulting Group Nov 6, 2026
- Knightscope Nov 6, 2026
- Curis Nov 6, 2026
- Intrusion Nov 5, 2026
- Karyopharm Therapeutics Nov 5, 2026
- Cognition Therapeutics Nov 5, 2026
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.